Document:

Executive Employment Agreement

 Exhibit 10.13 
 NEUROGESX, INC. 
 EXECUTIVE EMPLOYMENT AGREEMENT 

This Executive Employment Agreement (this “Agreement”), dated as of October 27, 2011, is entered into by and
between NEUROGESX, INC., a Delaware corporation (as supplemented by Section 13 hereof, the “Company”), and Stephen J. Peroutka, MD, PhD (the “Executive”). 

The Board of Directors of the Company (the “Board”) has determined that it is in the best interests of the Company and
its shareholders to ensure that the Company will have the continued dedication of the Executive. The Board believes it is imperative to diminish the inevitable distraction of the Executive arising from the personal uncertainty and insecurity that
arises in the absence of any assurance of job security by providing the Executive with reasonable compensation and benefit arrangements in the event of termination of the Executive’s employment by the Company under certain defined
circumstances, including a Change of Control. 
 In order to accomplish these objectives, the Board has caused the Company to
enter into this Agreement. 
  

	1.	Definitions 

 1.1
“Change of Control” shall have the definition set forth in Appendix A hereto, which is hereby incorporated by reference. 
 1.2 “Change of Control Date” shall mean the first date on which a Change of Control occurs. 
 1.3 “Employment Period” shall mean the eighteen (18) month period commencing on the Change of Control Date and ending on the eighteenth monthly anniversary of such date. 

 

	2.	Term 

 The initial term of
this Agreement (the “Initial Term”) shall be for a period of three (3) years from November 9, 2011, (the Effective Date); provided, however, that this Agreement shall automatically renew for successive additional three
(3) year periods (“Renewal Terms”) unless notice of nonrenewal is given by either party to the other party at least ninety (90) days prior to the end of the Initial Term or any Renewal Term; and provided, further, that if
a Change of Control occurs during the Term, the Term shall automatically extend for the duration of the Employment Period. The “Term” of this Agreement shall be the Initial Term plus all Renewal Terms and, if applicable, the
duration of the Employment Period. At the end of the Term, this Agreement shall terminate without further action by either the Company or the Executive. Notwithstanding any other provisions of this Agreement, the terms and conditions of this
Agreement shall not be in effect until the Effective Date, and the Executive shall not have any of the rights set forth herein (including any rights to severance, acceleration of vesting or otherwise) until such date, provided that the Company may
grant the Initial Option and Initial RSU (each as defined below) prior to the Effective Date. 

	3.	Employment 

 3.1
Position and Duties 
 (a) Executive will serve as Executive Vice President and Chief Medical Officer of the Company.
Executive will render such business and professional services in the performance of his duties, consistent with Executive’s position within the Company, as will reasonably be assigned to him by the Board. 

(b) During the Employment Period, the Executive’s position, authority, duties and responsibilities shall be at least commensurate in
all material respects with the most significant of those held, exercised and assigned at any time during the ninety (90) day period immediately preceding the Change of Control Date, provided, however, that a mere change of Executive’s
title or reporting relationship in connection with a Change of Control shall not be considered to be a breach of this Section 3.1. 
 3.2 Employment at Will 
 The Executive and the Company acknowledge that,
except as may otherwise be provided under any other written agreement between the Executive and the Company, the employment of the Executive by the Company or its affiliated companies is “at will” and may be terminated by either the
Executive or the Company or its affiliated companies at any time with or without cause. Moreover, if prior to the Change of Control Date, the Executive’s employment with the Company or its affiliated companies terminates for any reason, then
the Executive shall have no further rights under this Agreement with respect to provisions hereof that apply only after a Change of Control; provided, however, that the Company may not avoid liability for any termination payments that would have
been required during the Employment Period pursuant to Section 8.2 hereof by terminating the Executive prior to the Employment Period where such termination is carried out in anticipation of a Change of Control and is not for Cause. 

 

	4.	Attention and Effort 

During the Term, and excluding any periods of vacation and sick leave to which the Executive is entitled, the Executive will devote all of
the Executive’s productive time, ability, attention and effort to the business and affairs of the Company and the discharge of the responsibilities assigned to the Executive, hereunder, and will seek to perform faithfully and efficiently such
responsibilities. It shall not be a violation of this Agreement for the Executive to (a) serve on corporate, civic or charitable boards or committees, provided that the Executive shall not serve on more than two (2) corporate boards or
committees thereof without the prior approval of the Board, (b) deliver lectures, fulfill speaking engagements or teach at educational institutions, (c) manage personal investments, or (d) engage in activities permitted by the
policies of the Company or as specifically permitted by the Company, so long as such activities do not significantly interfere with the performance of the Executive’s responsibilities in accordance with this Agreement. It is expressly
understood and agreed that to the extent any such activities have been conducted by the Executive prior to the Term, the continued conduct 

 
of such activities (or the conduct of activities similar in nature and scope thereto) during the Term shall not thereafter be deemed to interfere with the performance of the Executive’s
responsibilities to the Company. 
  

	5.	Compensation 

 5.1
Compensation in General 
  

	 	(a)	Salary 

 The
Executive’s base salary will initially be $385,000 (three hundred and eighty five thousand). The base salary will be paid periodically in accordance with the Company’s normal payroll practices and will be subject to the usual, required
withholding. Executive’s salary will be subject to review and adjustments will be made based upon the Company’s normal performance review practices. 
  

	 	(b)	Performance Bonus 

Executive will be eligible to receive an annual bonus and other bonuses, less applicable withholding taxes, as determined by the Board or
any committee thereof in the Board’s or such committee’s sole discretion. Executive’s annual target performance bonus will initially be 50% of Executive’s base salary, although the amount of any payment will be dependent upon
actual performance as determined by the Board or an applicable committee thereof. The annual performance bonus for 2011 will be pro-rated for the portion of such fiscal year in which Executive actually performed services to the Company as its
Executive Vice President and Chief Medical Officer. 
  

	 	(c)	Equity Compensation 

Executive will be eligible to receive stock and option grants, and other equity compensation awards, as determined by the Board or any
committee thereof in the Board’s or such committee’s sole discretion. 
  

	 	(i)	Initial Option Award 

 It
will be recommended at the first regularly scheduled meeting of the Board or an appropriate committee thereof (the “Meeting”) occurring after the date of entry into this Agreement by the Company and Executive that Executive be
granted an option (the “Initial Option”) to purchase 225,000 shares of the Company’s common stock (the “Initial Option Shares”). The price per share of any approved Initial Option will be determined at such
meeting in the sole discretion of the Board or any committee thereof. It will be recommended that the Initial Option Shares shall vest as follows: one quarter (1/4) of the Initial Option Shares shall vest on the first anniversary of the date
that Executive begins performing services as Executive Vice President and Chief Medical Officer, and one forty-eighth (1/48) of the Initial Option Shares shall vest each monthly anniversary thereafter until all such Initial Option Shares have
vested, based on Executive’s continued status as a service provider to the Company on each such date. 

	 	(ii)	Initial Restricted Stock Unit Grant 

 It will be recommended at the Meeting that you be granted restricted stock units (the “Initial RSU”) for 75,000 shares of the Company’s common stock (the “Initial RSU
Shares”). It will be recommended that the Initial RSU Shares shall vest as follows: one quarter (1/4) of the Initial RSU Shares shall vest on the first anniversary of the date that Executive begins performing services as Executive V.P.
and Chief Medical Officer, and one quarter (1/4) of the Initial RSU Shares shall vest each yearly anniversary thereafter until all such Initial RSU Shares have vested, based on Executive’s continued status as a service provider to the
Company on each such date. 
  

	 	(iii)	Initial Grants Subject to Company Equity Compensation Plans 

 Grants for the Initial Option and Initial RSU will be subject to the Company’s equity compensation plans and forms of grant agreements approved for use thereunder. 

5.2 Compensation During Employment Period 
 As long as the Executive remains employed by the Company during the Employment Period, the Company agrees to pay or cause to be paid to the Executive, and the Executive agrees to accept in exchange for
the services rendered hereunder by the Executive, the following compensation: 
  

	 	(a)	Salary 

 As long as the
Executive remains employed by the Company during the Employment Period, the Executive shall receive an annual base salary (the “Annual Base Salary”), at least equal to the annual salary established by the Board or the Compensation
Committee of the Board (the “Compensation Committee”) for the fiscal year in which the Change of Control Date occurs. The Annual Base Salary shall be paid in substantially equal installments and at the same intervals as the salaries
of other executives of the Company are paid. The Annual Base Salary shall be reviewed at least annually and shall determine in good faith and consistent with any generally applicable Company policy any increases for future years. 

 

	 	(b)	Performance Bonus 

 In
addition to the Annual Base Salary, and as long as the Executive remains employed by the Company during the Employment Period, the Executive shall be awarded, for each fiscal year ending during the Employment Period, an annual performance bonus (the
“Annual Performance Bonus”) in cash at least equal to the average annualized (for any fiscal year consisting of less than twelve (12) full months) bonus paid or payable to the Executive by the Company and its affiliated
companies in respect of the Executive’s performance during the three fiscal years (or such shorter period of employment) immediately preceding the fiscal year in which the Change of Control Date occurs. Each Annual Performance Bonus shall be
paid in the fiscal year following the fiscal year for which the Annual Performance Bonus is awarded, but no later than the fifteenth day of the third month of such subsequent fiscal year, unless the Executive shall elect to defer the receipt of the
Annual Performance Bonus in accordance with the terms of any deferred compensation program of the Company. 

	6.	Benefits 

 6.1
Incentive, Retirement and Welfare Benefit Plans; Vacation 
 As long as the Executive remains employed by the Company
(including during the Employment Period), the Executive shall be entitled to participate, subject to and in accordance with applicable eligibility requirements, in such fringe benefit programs as shall be generally made available to other executives
of the Company and its affiliated companies from time to time (including during the Employment Period) by action of the Board (or any person or committee appointed by the Board to determine fringe benefit programs and other emoluments), including,
without limitation, paid vacations; any stock purchase, savings or retirement plan, practice, policy or program; and all welfare benefit plans, practices, policies or programs (including, without limitation, medical, prescription, dental,
disability, salary continuance, employee life, group life, accidental death and travel accident insurance plans or programs). 

6.2 Expenses 
 As long as the Executive remains employed by the Company (including during the Employment Period), the Executive shall be entitled to receive prompt reimbursement for all reasonable employment expenses
incurred by the Executive in accordance with the policies, practices and procedures of the Company and its affiliated companies in effect for the executives of the Company and its affiliated companies (including during the Employment Period).
Without limitation on the foregoing, reimbursement shall be made no later than the end of the fourth month of the year following the year in which the expense was incurred. 
 6.3 Reasonable and Customary Temporary Living Expenses 
 In recognition that
Executive will be relocating to the San Francisco Bay Area and in lieu of reimbursed relocation expenses, for the first year of full time employment, Executive will be entitled to be reimbursed for usual and customary living expenses to include
local housing, travel to and from Executives current home. The amount of such living expenses will be approved on a case by case basis but is anticipated to not exceed $3000 per month. 

 

	7.	Termination 

 During the
Term, employment of the Executive may be terminated as follows, but, in any case, the provisions set forth in Section 10 hereof shall survive the termination of this Agreement and the termination of the Executive’s employment with the
Company: 
 7.1 Termination by the Company or the Executive 

At any time during the Term, the Company may terminate the employment of the Executive with or without Cause (as defined below), and the
Executive may terminate the Executive’s employment for Good Reason (as defined below) or for any reason, upon giving a Notice of Termination (as defined below). 

 7.2 Automatic Termination 

This Agreement and the Executive’s employment during the Term shall terminate automatically upon the death or Total Disability of
the Executive. The term “Total Disability” as used herein shall mean the Executive’s inability (with such accommodation as may be required by law and which places no undue burden on the Company), as determined by a physician
selected by the Company and acceptable to the Executive, to perform the Executive’s essential duties (including as set forth in Section 3.1 hereof, which duties are hereby acknowledged to be essential to the Executive’s position and
that the Executive’s ability to perform those duties is the essence of this Agreement) for a period or periods aggregating twelve (12) weeks in any three hundred sixty-five (365) day period as a result of physical or mental illness,
loss of legal capacity or any other cause beyond the Executive’s control, unless the Executive is granted a leave of absence by the Board. 
 7.3 Notice of Termination 
 Any termination by the Company or by the
Executive during the Term shall be communicated by a Notice of Termination to the other party given in accordance with Section 12 hereof. The term “Notice of Termination” shall mean a written notice that (a) indicates the
specific termination provision in this Agreement relied upon and (b) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive’s employment under the
provision so indicated. The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance that contributes to a showing of Good Reason or Cause shall not waive any right of the Executive or the Company
hereunder or preclude the Executive or the Company from asserting such fact or circumstance in enforcing the Executive’s or the Company’s rights hereunder. 
 7.4 Date of Termination 
 “Date of Termination” means (a) if the
Executive’s employment is terminated by reason of death, the last day of the calendar month in which the Executive’s death occurs, (b) if the Executive’s employment is terminated by reason of Total Disability, immediately upon a
determination by the Company of the Executive’s Total Disability, and (c) in all other cases, ten (10) days after the date of personal delivery or mailing of the Notice of Termination. The Executive’s employment and performance
of services will continue during such ten (10) day period; provided, however, that the Company may, upon notice to the Executive and without reducing the Executive’s compensation during such period, excuse the Executive from any or all of
the Executive’s duties during such period. Notwithstanding anything contained in this Agreement to the contrary, the date on which a “separation from service” (“Separation from Service”) pursuant to Section 409A
of the Internal Revenue Code of 1986, as amended (“Code Section 409A”), occurs shall be the “Date of Termination” or termination of employment for purposes of determining the timing of payments under this Agreement to
the extent necessary to have such payments and benefits under this Agreement be exempt from the requirements of Code Section 409A or comply with the requirements of Code Section 409A. 

	8.	Termination Payments 

 In the event of
termination of the Executive’s employment during the Term (including the Employment Period), all compensation and benefits set forth in this Agreement shall terminate except as specifically provided in this Section 8. 

8.1 Termination by the Company Outside of Employment Period Other Than for Cause or by the Executive for Good Reason 

Except as set forth in Section 3.2 and 8.2 hereof, if during the Term the Company terminates the Executive’s employment other than for Cause or
the Executive terminates the Executive’s employment for Good Reason, the Executive shall be entitled to: 
 (a) receive
payment of the following accrued obligations (the “Accrued Obligations”): 
 (i) the Executive’s then
current annual base salary (or if the termination is governed by Section 8.2 below, the Annual Base Salary) through the Date of Termination to the extent not theretofore paid; 

(ii) any compensation previously deferred by the Executive (together with accrued interest or earnings thereon, if any); and 

(iii) any accrued vacation pay that would be payable under the Company’s standard policy, in each case to the extent not theretofore
paid; 
 (b) have the Company pay for twelve (12) months after the Date of Termination or until the Executive qualifies for
comparable medical and dental insurance benefits from another employer, whichever occurs first, the Executive’s premiums for health insurance benefit continuation for the Executive and the Executive’s family members, if applicable, that
the Company provides to the Executive under the provisions of the federal Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), to the extent that the Company would have paid such premiums had the Executive
remained employed by the Company (such continued payment is hereinafter referred to as “8.1 COBRA Continuation”); 
 (c) salary continuation as severance pay (subject to the limitations set forth in Section 8.6, below) at a rate equal to one (1) times the Executive’s then current base salary for the
fiscal year in which the Date of Termination occurs; 
 (d) have all of Executive’s then outstanding options be deemed
amended to extend the post-termination option exercise period during which the Executive can exercise such options to twelve (12) months; and 
 (e) with respect to all awards issued under the Company’s equity incentive plans and outstanding immediately prior to the Date of Termination that provide for vesting, restriction lapse, meeting of
performance goals or meeting of other vesting criteria to be met or achieved solely on the basis of the time over which the Executive remains a service provider to the Company, have such awards immediately vest, have their restrictions lapse, and
have their performance goals or other vesting criteria achieved at target levels, and other terms and conditions met, as of the Date of Termination as if the Executive had remained a service 

 
provider for an additional twelve (12) months following the Date of Termination (for example, and for the avoidance of doubt, if the Executive had an option to purchase 48,000 shares of
Common Stock that vested at a 1/48th per month rate
based on the Executive remaining a service provider as of such dates, and Executive was terminated in a manner that would trigger Executive’s rights under this Section 8.1(e) immediately after the 20th month of vesting of such option, the vesting of such option would
accelerate as of the Date of Termination so that as of the Date of Termination the option would be vested with respect to 32,000 shares (20 months of vesting as of the date of date of termination plus an additional 12 months of vesting acceleration
pursuant to this Section 8.1(e)). 
 8.2 Termination During Employment Period by the Company Other Than for Cause or by
the Executive for Good Reason 
 Except as set forth in Section 3.2, if the Date of Termination occurs during an
Employment Period and such termination is by the Company other than for Cause or by the Executive for Good Reason, in lieu of the payments set forth in Section 8.1 above the Executive shall be entitled to: 

(a) receive payment of the Accrued Obligations; 
 (b) have the Company pay for twelve (12) months after the Date of Termination or until the Executive qualifies for comparable medical and dental insurance benefits from another employer, whichever
occurs first, the Executive’s premiums for health insurance benefit continuation for the Executive and the Executive’s family members, if applicable, that the Company provides to the Executive under the provisions of COBRA, to the extent
that the Company would have paid such premiums had the Executive remained employed by the Company (such continued payment is hereinafter referred to as “8.2 COBRA Continuation”); 

(c) an amount as severance pay (subject to the limitations set forth in Section 8.6, below) equal to one (1) times
Executive’s then current annual target performance bonus payable with respect to the fiscal year in which the Date of Termination occurs (the “Total Bonus Severance Amount”); 

(d) salary continuation as severance pay (subject to the limitations set forth in Section 8.6, below) at a rate equal to one
(1) times the Annual Base Salary for the fiscal year in which the Date of Termination occurs; 
 (e) have all of
Executive’s then outstanding options be deemed amended to extend the post-termination option exercise period during which the Executive can exercise such options to twelve (12) months; and 

(f) with respect to all awards issued under the Company’s equity incentive plans and outstanding immediately prior to the Date of
Termination, Executive will immediately vest in and have the right to exercise such awards in full, all restrictions will lapse, and all performance goals or other vesting criteria will be deemed achieved at target levels and all other terms and
conditions met. 

 8.3 Termination for Cause or Other Than for Good Reason 

If during the Term (including the Employment Period) the Executive’s employment shall be terminated by the Company for Cause or by
the Executive for other than Good Reason, this Agreement shall terminate without further obligation on the part of the Company to the Executive, other than the Company’s obligation to pay the Executive the Accrued Obligations to the extent
theretofore unpaid. 
 8.4 Expiration of Term 
 In the event the Executive’s employment is not terminated prior to expiration of the Term, this Agreement shall terminate without further obligation on the part of the Company to the Executive.

 8.5 Termination Because of Death or Total Disability 

If during the Term the Executive’s employment is terminated by reason of the Executive’s death or Total Disability, this
Agreement shall terminate automatically without further obligation on the part of the Company to the Executive or the Executive’s legal representatives under this Agreement, other than the Company’s obligation to pay the Executive the
Accrued Obligations (which shall be paid to the Executive’s estate or beneficiary, as applicable in the case of the Executive’s death) and to provide 8.1 COBRA Continuation (if such termination occurs outside of an Employment Period) or
8.2 COBRA Continuation (if such termination occurs during an Employment Period), as applicable. 
 8.6 Payment Schedule

 All payments of Accrued Obligations, or any portion thereof payable pursuant to this Section 8,
other than deferred compensation described in Section 8. 1(a)(iii) hereof, shall be made to the Executive within ten (10) working days of the Date of Termination. Deferred compensation described in Section 8.1(a)(iii) hereof shall be
payable pursuant to the terms of any applicable deferred compensation program. Any severance payments payable to the Executive pursuant to Section 8.1(c) and Section 8.2(d) hereof shall be made to the Executive in the form of salary
continuation, payable at normal payroll intervals during the twelve (12) month period following the Date of Termination. Any severance payments payable to the Executive pursuant to Section 8.2(c) hereof shall be made to the Executive at
the time that the Company pays its executive officers (as a group) their annual performance bonus (the “Payment Date”) with respect to the fiscal year in which the Date of Termination occurs provided that if the Company does not pay
its executive officers an annual bonus with respect to a fiscal year, the Executive shall be paid the applicable portion of the Total Bonus Severance Amount no later than the 15th calendar day of the third month of the fiscal year following the fiscal year with respect to which the Company did not
pay its executive officers an annual performance bonus. Notwithstanding the preceding provisions of this Section 8, if any payment or benefit pursuant to this Agreement constitutes a “deferral of compensation” subject to Code
Section 409A (after taking into account, to the maximum extent possible, any applicable exemptions) (a “409A Payment”) treated as payable to a Specified Employee (as defined in Section 21.1 hereof) upon Separation from
Service, the provisions of Section 21.1 hereof shall apply. Section 8.9 hereof must be satisfied to receive payments and benefits under this Agreement. 

 8.7 Cause 
 For purposes of this Agreement, “Cause” means cause given by the Executive to the Company and shall include, without limitation, the occurrence of one (1) or more of the following
events: 
 (a) a clear refusal to carry out any material lawful duties of the Executive or any directions of the Board
reasonably consistent with those duties; 
 (b) persistent failure to carry out any lawful duties of the Executive or any
directions of the Board reasonably consistent with those duties; provided, however, that the Executive has been given reasonable notice and opportunity to correct any such failure; 

(c) violation by the Executive of a state or federal criminal law involving the commission of a crime against the Company or any other
felonious criminal act involving moral turpitude; 
 (d) current abuse by the Executive of alcohol or controlled substances;
deception, fraud, material misrepresentation or material dishonesty by the Executive; or any incident materially compromising the Executive’s reputation or ability to represent the Company with investors, customers or the public; 

(e) any other material violation of any provision of this Agreement by the Executive, subject to the notice and opportunity-to-cure
requirements of Section 11 hereof. 
 8.8 Good Reason 

For purposes of this Agreement, “Good Reason” means: 

(a) material reduction of the Executive’s annual base salary to a level below the level in effect on the date of this Agreement,
regardless of any change in the Executive’s duties or responsibilities; 
 (b) the assignment to the Executive of any
duties materially inconsistent with the Executive’s position, authority, duties or responsibilities or any other action by the Company that results in a material diminution in such position, authority, duties or responsibilities, excluding for
this purpose (i) an isolated and inadvertent action not taken in bad faith and that is remedied by the Company promptly after receipt of notice thereof given by the Executive (ii) a mere change of title or reporting status in connection
with a Change of Control; 
 (c) the Company’s requiring the Executive to be based at any office or location more than
fifty (50) miles from the city in which the Executive is currently employed by the Company, which, for the avoidance of doubt, is San Mateo, California; 

 (d) any failure by the Company to comply with and satisfy Section 13 hereof; provided,
however, that the Company’s successor has received at least ten (10) days’ prior written notice from the Company or the Executive of the requirements of Section 13hereof; or 

(e) any other material violation of any provision of this Agreement by the Company; provided, however, that the Executive has notified
the Company of such salary reduction, assignment, failure, situation or violation within ninety (90) days of its occurrence and there has been compliance with the notice and opportunity-to-cure requirements of Section 11 hereof.

 8.9 Excess Parachute Limitation 
 In the event that the severance and other benefits provided for in this Agreement or otherwise payable to Executive (i) constitute “parachute payments” within the meaning of
Section 280G of the Internal Revenue Code of 1986, as amended (the “Code”) and (ii) but for this Section 8.8, would be subject to the excise tax imposed by Section 4999 of the Code, then Executive’s benefits
hereunder shall be either: 
 (a) delivered in full, or 

(b) delivered as to such lesser extent which would result in no portion of such severance benefits being subject to excise tax under
Section 4999 of the Code, 
 whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes
and the excise tax imposed by Section 4999, results in the receipt by Executive on an after-tax basis, of the greatest amount of severance benefits, notwithstanding that all or some portion of such severance benefits may be taxable under
Section 4999 of the Code. If a reduction in the severance and other benefits constituting “parachute payments” is necessary so that no portion of such severance benefits is subject to the excise tax under Section 4999 of the
Code, the reduction shall occur in the following order unless the Company determines in writing a different order: (1) reduction of cash payments under this Agreement; (2) cancellation of some or all accelerated vesting of stock awards;
and (3) reduction of employee benefits. In the event that acceleration of vesting of stock and option grants, and other equity compensation awards (“Awards”), compensation is to be reduced, such acceleration of vesting shall be
cancelled in the reverse order of the date of grant of Executive’s Awards. 
 Unless the Company and Executive otherwise agree in writing,
any determination required under this Section 8.8 shall be made in writing by the Company’s independent public accountants immediately prior to Change of Control (the “Accountants”), whose determination shall be conclusive
and binding upon Executive and the Company for all purposes. For purposes of making the calculations required by this Section 8.8, the Accountants may make reasonable assumptions and approximations concerning applicable taxes and may rely on
reasonable, good faith interpretations concerning the application of Sections 280G and 4999 of the Code. The Company and Executive shall furnish to the Accountants such information and documents as the Accountants may reasonably request in
order to make a determination under this Section 8.8. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 8.8. 

 8.10 General Release of Claims 

As a condition to receiving the payments and benefits under this Section 8 other than Accrued Obligations as described in Sections
8.1(a)(i) and 8.1(a)(iii) hereof, the Executive shall execute (and not later revoke) a general release and waiver of all claims against the Company (other than claims under this Agreement), which release and waiver shall be in a form satisfactory to
the Company, in its reasonable discretion, and delivered to the Company no later than the seventh day of the third month of the fiscal year following the year in which the Date of Termination occurs. By way of example and not limitation, the general
release and waiver of claims will include any claims for wages, bonuses, employment benefits, or damages of any kind whatsoever, arising out of any contracts, express or implied, any covenant of good faith and fair dealing, express or implied, any
theory of wrongful discharge, any legal restriction on the Company’s right to terminate employment, or any federal, state or other governmental statute or ordinance, including, without limitation, Title VII of the Civil Rights Act of 1964,
the federal Age Discrimination in Employment Act, the Americans with Disabilities Act, the Family and Medical Leave Act, the Washington Law Against Discrimination, or any other legal limitation on the employment relationship. To the extent any
payment or benefit is a 409A Payment, the provisions of Section 21.3 hereof shall apply. 
  

	9.	Representations, Warranties and Other Conditions 

 In order to induce the Company to enter into this Agreement, the Executive represents and warrants to the Company as follows: 
 9.1 Health 
 The Executive is in good health and knows of no physical or
mental disability that, with any accommodation that may be required by law and that places no undue burden on the Company, would prevent the Executive from fulfilling the Executive’s obligations hereunder. The Executive agrees, if the Company
requests, to submit to reasonable periodic medical examinations by a physician or physicians designated by, paid for and arranged by the Company. The Executive agrees that each examination’s medical report shall be provided to the Company.

 9.2 No Violation of Other Agreements 
 The Executive represents that neither the execution nor the performance of this Agreement by the Executive will violate or conflict in any way with any other agreements or obligations by which the
Executive may be bound. 
  

	10.	Nondisclosure; Return of Materials 

 10.1 Nondisclosure 
 Except as required by the Executive’s employment
with the Company, the Executive will not, at any time during the term of employment by the Company, or at any time thereafter, 

 
directly, indirectly or otherwise, use, communicate, disclose, disseminate, lecture upon or publish articles relating to any confidential, proprietary or trade secret information of the Company
without the prior written consent of the Company. The Executive understands that the Company will be relying on this Agreement in continuing the Executive’s employment, paying the Executive’s compensation, granting the Executive any
promotions or raises, or entrusting the Executive with any information that helps the Company compete with others. 
 10.2
Return of Materials 
 All documents, records, notebooks, notes, memoranda, drawings or other documents made or compiled by
the Executive at any time while employed by the Company, or in the Executive’s possession, including any and all copies thereof, shall be the property of the Company and shall be held by the Executive in trust and solely for the benefit of the
Company, and shall be delivered to the Company by the Executive upon termination of employment or at any other time upon request by the Company. 
  

	11.	Notice and Cure of Breach 

Whenever a breach of this Agreement by either party is relied upon as justification for any action taken by the other party pursuant to
any provision of this Agreement, other than clause (a), (b), (c) or (d) of Section 8.7 hereof, before such action is taken, the party asserting the breach of this Agreement shall give the other party at least thirty
(30) days’ prior written notice of the existence and the nature of such breach before taking further action hereunder and shall give the party purportedly in breach of this Agreement the opportunity to correct such breach during the thirty
(30) day period. 
  

	12.	Form of Notice 

 Every
notice required by the terms of this Agreement shall be given in writing by serving the same upon the party to whom it was addressed personally or by registered or certified mail, return receipt requested, at the address set forth below or at such
other address as may hereafter be designated by notice given in compliance with the terms hereof: 
  

			
	If to Executive	  	 Stephen J. Peroutka, MD, PhD

Address to be provided to Company separately in writing

		
	If to the Company	  	 NeurogesX, Inc.
 2215
Bridgepointe Parkway, Suite 200
 San Mateo, CA 94404
 Attn: Legal Affairs

		
	With Copy to	  	 Morrison & Foerster
 755
Page Mill Road
 Palo Alto, CA 94304

Attn: Michael O’Donnell

 Except as set forth in Section 7.4 hereof, if notice is mailed, such notice shall be effective upon
mailing. 
  

	13.	Assignment 

 This
Agreement is personal to the Executive and shall not be assignable by the Executive. The Company shall assign to and require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all the
business and/or assets of the Company to assume expressly and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this
Agreement, “Company” shall mean NeurogesX, Inc. and any affiliated company or successor to its business and/or assets as aforesaid that assumes and agrees to perform this Agreement by contract, operation of law or otherwise; and as
long as such successor assumes and agrees to perform this Agreement, the termination of the Executive’s employment by one such entity and the immediate hiring and continuation of the Executive’s employment by the succeeding entity shall
not be deemed to constitute a termination or trigger any severance obligation under this Agreement. All the terms and provisions of this Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their
respective successors and permitted assigns 
  

	14.	Waivers 

 No delay or
failure by any party hereto in exercising, protecting or enforcing any of its rights, titles, interests or remedies hereunder, and no course of dealing or performance with respect thereto, shall constitute a waiver thereof. The express waiver by a
party hereto of any right, title, interest or remedy in a particular instance or circumstance shall not constitute a waiver thereof in any other instance or circumstance. All rights and remedies shall be cumulative and not exclusive of any other
rights or remedies. 
  

	15.	Amendments in Writing 

 No
amendment, modification, waiver, termination or discharge of any provision of this Agreement, or consent to any departure therefrom by either party hereto, shall in any event be effective unless the same shall be in writing, specifically identifying
this Agreement and the provision intended to be amended, modified, waived, terminated or discharged and signed by the Company and the Executive, and each such amendment, modification, waiver, termination or discharge shall be effective only in the
specific instance and for the specific purpose for which given. No provision of this Agreement shall be varied, contradicted or explained by any oral agreement, course of dealing or performance or any other matter not set forth in an agreement in
writing and signed by the Company and the Executive. 

	16.	Applicable Law 

 This
Agreement shall in all respects, including all matters of construction, validity and performance, be governed by, and construed and enforced in accordance with, the laws of the State of California, without regard to any rules governing conflicts of
laws. 
  

	17.	Attorneys’ Fees 

 If
it becomes necessary to pursue or defend any legal proceeding in order to resolve a dispute arising under this Agreement, the prevailing party in any such proceeding shall be entitled to recover its reasonable costs and attorneys’ fees. To the
extent necessary to prevent the Executive from being subject to any additional tax pursuant to Code Section 409A(a)(l)(B), any amounts payable to the Executive pursuant to this paragraph shall be paid in no event later than the year following
the year during which such costs and fees were incurred. 
  

	18.	Severability 

 If any
provision of this Agreement shall be held invalid, illegal or unenforceable in any jurisdiction, for any reason, including, without limitation, the duration of such provision, its geographical scope or the extent of the activities prohibited or
required by it, then, to the full extent permitted by law, (a) all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intent of the parties hereto as
nearly as may be possible, (b) such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of any other provision hereof, and (c) any court or arbitrator having jurisdiction thereover shall
have the power to reform such provision to the extent necessary for such provision to be enforceable under applicable law. 
  

	19.	Entire Agreement 

 This
Agreement constitutes the entire agreement between the Company and the Executive with respect to the subject matter hereof, and all prior or contemporaneous oral or written communications, understandings or agreements between the Company and the
Executive with respect to such subject matter are hereby superseded and nullified in their entireties, except that the Proprietary Information and Invention Agreement between the Executive and the Company shall continue in full force and effect to
the extent not superseded by Section 10 hereof. 
  

	20.	Withholding 

 The Company
may withhold from any amounts payable under this Agreement such federal, state or local taxes as shall be required to be withheld pursuant to any applicable law or regulation. 

	21.	409A Interpretation Provision 

 The parties intend that this Agreement and the payments and benefits provided hereunder be exempt from the requirements of Code Section 409A to the maximum extent possible, whether pursuant to the
short-term deferral exception described in Treasury Regulation Section 1.409A-1 (b)(4), the involuntary separation pay plan exception described in Treasury Regulation Section 1.409A-1(b)(9)(iii), or otherwise. To the extent Code
Section 409A is applicable to this Agreement, the parties intend that this Agreement comply with the deferral, payout and other limitations and restrictions imposed under Code Section 409A. Notwithstanding anything herein to the contrary,
this Agreement is intended to be interpreted and operated to the fullest extent possible so that the payments and benefits under this Agreement either shall be exempt from the requirements of Code Section 409A or shall comply with the
requirements of such provision; provided, however, that notwithstanding anything to the contrary in this Agreement in no event shall the Company be liable to the Executive for or with respect to any taxes, penalties or interest that may be imposed
upon the Executive pursuant to Code Section 409A. 
 21.1 Payments to Specified Employees 

To the extent that any payment or benefit pursuant to this Agreement constitutes a 409A Payment treated as payable upon Separation from
Service, then, if on the date of the Executive’s Separation from Service, the Executive is a Specified Employee, then to the extent required for the Executive not to incur additional taxes pursuant to Code Section 409A, no such 409A
Payment shall be made to the Executive earlier than the earlier of (a) six (6) months after the Executive’s Separation from Service or (b) the date of the Executive’s death. Should this Section 21 result in the delay of
benefits, any such benefit shall be made available to the Executive by the Company during such delay period at the Executive’s expense. Should this Section 21.1 result in a delay of payments or benefits to the Executive, on the first day
any such payments or benefits may be made without incurring additional tax pursuant to Code Section 409A (the “409A Payment Date”), the Company shall make such payments and provide such benefits as provided for in this
Agreement, provided that any amounts that would have been payable earlier but for the application of this Section 21.1 shall be paid in a lump sum on the 409A Payment Date. For purposes of this Section 21.1, the term “Specified
Employee” shall have the meaning set forth in Code Section 409A, as determined in accordance with the methodology established by the Company. 
 21.2 Reimbursements 
 For purposes of complying with Code Section 409A
and without extending the payment timing otherwise provided in this Agreement, taxable reimbursements under this Agreement, subject to the following sentence and to the extent required to comply with Code Section 409A, will be made no later
than the end of the calendar year following the calendar year the expense was incurred. To the extent required to comply with Code Section 409A, any taxable reimbursements and any in-kind benefit under this Agreement will be subject to the
following: (a) payment of such reimbursements 

 
or in-kind benefits during one calendar year will not affect the amount of such reimbursements or in-kind benefits provided during any other calendar year (other than for medical reimbursement
arrangements as excepted under Treasury Regulation Section 1.409A-3(i)(1)(iv)(B) solely because the arrangement provides for a limit on the amount of expenses that may be reimbursed under such arrangement over some or all of the period the
arrangement remains in effect); (b) such right to reimbursements or in-kind benefits is not subject to liquidation or exchange for another form of compensation to the Executive; and (c) the right to reimbursements under this Agreement will
be in effect for the lesser of the time specified in this Agreement or ten (10) years plus the lifetime of the Executive. Any taxable reimbursements or in-kind benefits shall be treated as not subject to Code Section 409A to the maximum
extent provided by Treasury Regulation Section 1.409A-1(b)(9)(v) or otherwise under Code Section 409A. 
 21.3
Release 
 Subject to Section 21.1 hereof, (a) to the extent that the Executive is required to execute and deliver
a release to receive a 409A Payment and (b) this Agreement provides for such 409A Payment to be provided prior to the 55th day following the Executive’s Separation from Service, such 409A Payment will be provided upon the 55th day
following the Executive’s Separation from Service, provided that the release in the form acceptable to the Company, in its reasonable discretion, has been executed, delivered and effective prior to such time. To the extent there is a delay in
providing a 409A Payment because of the provisions of this Section 21.3, interest for the delay and the opportunity for the Executive to pay for benefits in the interim with subsequent reimbursement from the Company shall be provided in a
manner consistent with that set forth in Section 21.1 hereof. If a release is required for a 409A Payment and such release is not executed, delivered and effective by the 55th day following the Executive’s Separation from Service, such
409A Payment shall not be provided to the Executive to the extent that providing such 409A Payment would cause such 409A Payment to fail to comply with Code Section 409A. 
 21.4 No Acceleration; Separate Payments 
 No 409A Payment payable under
this Agreement shall be subject to acceleration or to any change in the specified time or method of payment, except as otherwise provided under this Agreement and consistent with Code Section 409A. If under this Agreement, a 409A Payment is to
be paid in two or more installments, for purposes of Section 409A, each installment shall be treated as a separate payment. 
  

	22.	Counterparts 

 This
Agreement may be executed in counterparts, each of which counterparts shall be deemed an original, but all of which together shall constitute one and the same instrument. 

 IN WITNESS WHEREOF, the parties have executed and entered into this Agreement effective on
the date first set forth above. 
  

			
	NEUROGESX, INC.
		
	By:	 	 /s/ Stephen Ghiglieri

		 	Name: Stephen Ghiglieri
		 	Its: Exec. V.P., COO & CFO
	
	EXECUTIVE
		
	By:	 	 /s/ Stephen J. Peroutka

		 	Name: Stephen J. Peroutka, MD, PhD

 APPENDIX A 
 For purposes of this Agreement, a “Change of Control” shall mean: 

(a) A “Board Change” that, for purposes of this Agreement, shall have occurred if a majority (excluding vacant seats) of
the seats on the Board are occupied by individuals who were neither (i) nominated by a majority of the Incumbent Directors nor (ii) appointed by directors so nominated. An “Incumbent Director” is a member of the Board who
has been either (i) nominated by a majority of the directors of the Company then in office or (ii) appointed by directors so nominated, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a
result of either an actual or threatened election contest (as such terms are used in former Rule 14a-ll of Regulation 14A promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) or other actual or
threatened solicitation of proxies or consents by or on behalf of a Person (as hereinafter defined) other than the Board; or 

(b) The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Exchange Act) (a
“Person”) of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of (i) fifty percent (50%) or more of either (A) the then outstanding shares of Common Stock of the Company (the
“Outstanding Company Common Stock”) or (B) the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors (the “Outstanding Company Voting
Securities”), in the case of either sub clause (A) or (B) of this clause (i), which acquisition is not approved in advance by a majority of the Incumbent Directors, or (ii) thirty-three percent (33%) or more of either
(A) the Outstanding Company Common Stock or (B) the Outstanding Company Voting Securities, in the case of either subclause (A) or (B) of this clause (ii), which acquisition is approved in advance by a majority of the Incumbent
Directors; provided, however, that the following acquisitions shall not constitute a Change of Control: (x) any acquisition by the Company, (y) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the
Company or any corporation controlled by the Company, or (z) any acquisition by any corporation pursuant to a reorganization, merger or consolidation, if, following such reorganization, merger or consolidation, the conditions described in
clauses (i), (ii) and (iii) of subsection (c) of this Appendix A are satisfied; or 
 (c) Approval by the
shareholders of the Company of a reorganization, merger or consolidation, in each case, unless, immediately following such reorganization, merger or consolidation, (i) more than sixty percent (60%) of, respectively, the then outstanding
shares of common stock of the corporation resulting from such reorganization, merger or consolidation and the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of directors
is then beneficially owned, directly or indirectly, by all or substantially all the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and the Outstanding Company Voting Securities
immediately prior to such reorganization, merger or consolidation in substantially the same proportion as their ownership immediately prior to such reorganization, merger or 

 
consolidation of the Outstanding Company Common Stock and the Outstanding Company Voting Securities, as the case may be, (ii) no Person (excluding the Company, any employee benefit plan (or
related trust) of the Company or such corporation resulting from such reorganization, merger or consolidation and any Person beneficially owning, immediately prior to such reorganization, merger or consolidation, directly or indirectly, thirty-three
percent (33%) or more of the Outstanding Company Common Stock or the Outstanding Company Voting Securities, as the case may be) beneficially owns, directly or indirectly, thirty-three percent (33%) or more of, respectively, the then
outstanding shares of common stock of the corporation resulting from such reorganization, merger or consolidation or the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election
of directors, and (iii) at least a majority of the members of the board of directors of the corporation resulting from such reorganization, merger or consolidation were the Incumbent Directors at the time of the execution of the initial
agreement providing for such reorganization, merger or consolidation; or 
 (d) Approval by the shareholders of the Company of
(i) a complete liquidation or dissolution of the Company or (ii) the sale or other disposition of all or substantially all the assets of the Company, other than to a corporation with respect to which immediately following such sale or
other disposition, (A) more than sixty percent (60%) of, respectively, the then outstanding shares of common stock of such corporation and the combined voting power of the then outstanding voting securities of such corporation entitled to
vote generally in the election of directors is then beneficially owned, directly or indirectly, by all or substantially all the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and the
Outstanding Company Voting Securities immediately prior to such sale or other disposition in substantially the same proportion as their ownership, immediately prior to such sale or other disposition, of the Outstanding Company Common Stock and the
Outstanding Company Voting Securities, as the case may be, (B) no Person (excluding the Company, any employee benefit plan (or related trust) of the Company or such corporation and any Person beneficially owning, immediately prior to such sale
or other disposition, directly or indirectly, thirty-three percent (33%) or more of the Outstanding Company Common Stock or the Outstanding Company Voting Securities, as the case may be) beneficially owns, directly or indirectly, thirty-three
percent (33%) or more of, respectively, the then outstanding shares of common stock of such corporation or the combined voting power of the then outstanding voting securities of such corporation entitled to vote generally in the election of
directors, and (C) at least a majority of the members of the board of directors of such corporation were approved by a majority of the Incumbent Directors at the time of the execution of the initial agreement or action of the Board providing
for such sale or other disposition of the Company’s assets.Employment Agreement

 Exhibit 10.1 
 March 14, 2012 
 Dear Lori, 
 I am pleased to offer you the position of Executive Vice President, Human Resources for Conceptus, Inc. Your starting salary will be $22,500.00 per month, or $270,000.00 annually, subject to all Federal,
State and other applicable taxes and withholdings, payable on bi-weekly basis. In this capacity, you will report directly to Keith Grossman, President and CEO. Should you accept this offer, you will begin work as a regular, exempt employee.

 You will also be eligible to receive a bonus of up to 50% of your salary (pro-rated to your start date). The payout of the bonus is dependent
upon the Company achieving its 2012 Goals and Objectives as well as you achieving your department Goals and Objectives. I will further discuss with you the bonus program upon your hire. Also, as part of this offer, you will be provided with a Change
of Control Agreement provided to other executives at your level. In addition, your compensation package will be reviewed during the normal executive review time, which usually takes place in February. 

The Company will grant to you stock-settled, stock appreciation rights (SARs) 100,000 shares of Conceptus, Inc. The terms of the stock appreciation
rights are similar to stock options, but provide more flexibility in accordance with the Conceptus stock option plan. You will be given a copy of this plan at the time of your grant. According to the terms of that stock appreciation right,
your exercise price will be set based on the market closing price of Conceptus on the grant date, which will be your first day of employment, and you will become 12.50% vested after 6 months of employment, and then 1/48th per month thereafter
such that you will be fully vested at four years. Your vesting will commence as of your first day of employment with Conceptus. 
 This offer is
subject to approval of the Conceptus Board of Directors. 
 As a regular employee of Conceptus, Inc., you will be eligible to participate in a
number of Company sponsored benefits, which include: medical, dental, vision, life and long term disability insurance coverage. These benefits are effective the first day of your employment. You will also be eligible to join our 401(k) program and
participate in our employee stock purchase plan. 
 Employment with Conceptus is for no specific period of time. As a result, either you or
Conceptus, Inc. is free to terminate your employment relationship at any time for any reason, with or without cause. This is the full and complete agreement between us on this term. Although your job duties, titles, compensation and benefits, as
well as Conceptus’ personnel policies and procedures may change from time to time, the “at-will” nature of your employment may only be changed in an express written form signed by you and the President of the Company. 

Your employment pursuant to this offer is contingent on your executing the enclosed Proprietary Information and Inventions Agreement and upon your
providing the Company with the legally required proof of your identity and authorization to work in the United States, as well as completing a brief background check. Please provide the appropriate verification documents on your first day of
employment. 

 This letter sets forth the terms of your employment with us and supersedes any prior representations or
agreements, whether written or oral. To accept this offer, please sign and return this letter me. This offer, if not accepted, will expire at 12:00pm (noon) on March 22, 2012. We would expect your start date to be approximately March 26,
2012 or such other date as we mutually agree. Also, this offer is contingent upon completion of your reference checks as well as a background checks. 
 Lori, I look forward to having you join the Conceptus team, and know that you can make an enormous contribution to our success. If you have any questions, please call me. 

Sincerely, 
 D. Keith Grossman 

President and CEO 
 I have read and accept this
employment offer. 
  

					
	 /s/ Lori M. Ciano
	  	 March 26, 2012
	  	 March 26, 2012

	Lori M. Ciano	  	Date	  	Start Date

  

			
	Enclosures:	  	Change in Control Template
		  	Proprietary Information and Inventions Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00201-of-00352.parquet"}]]